Vapitadine

Drug Profile

Vapitadine

Alternative Names: Hivenyl; R 129160; Vapitadine dihydrochloride

Latest Information Update: 27 Apr 2011

Price : $50

At a glance

  • Originator Johnson & Johnson
  • Developer Stiefel Laboratories
  • Class Antiallergics; Antihistamines; Benzazepines; Piperidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Pruritus; Urticaria

Most Recent Events

  • 22 Jul 2009 Stiefel Laboratories has been acquired by GlaxoSmithKline
  • 09 Apr 2008 Final efficacy data from a phase II trial in urticaria released by Barrier Therapeutics
  • 11 Feb 2008 Phase-II clinical trials in Urticaria in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top